+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Phosphodiesterase (PDE) inhibitors Market 2019-2023 - Product Image

Global Phosphodiesterase (PDE) inhibitors Market 2019-2023

  • ID: 4804068
  • Report
  • Region: Global
  • 134 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Bayer AG
  • Eli LillyCo.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Vivus Inc.
  • MORE

Global Phosphodiesterase (PDE) inhibitors Market: About this market

Phosphodiesterase inhibitors represent a drug class comprising drugs with a similar mechanism of action i.e. by inhibiting PDE enzymes. The phosphodiesterase inhibitors market analysis considers sales from oral, topical, and other RoA. This analysis also considers the sales of phosphodiesterase inhibitors in Asia, Europe, North America, and ROW. In 2018, the oral segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as low cost, and accurate dosage and stability will play a significant role in the oral segment to maintain its market position. Also, our global phosphodiesterase inhibitors market report also looks at factors such as growing adoption of poor lifestyle habits, rising prevalence of erectile dysfunction (ED), and availability of next-generation PDE inhibitors. However, potent drug interactions of PDE inhibitors, side-effects associated with PDE inhibitors, and launch of generics may hamper the growth of the phosphodiesterase inhibitors industry over the forecast period.

Global Phosphodiesterase (PDE) inhibitors Market: Overview

Rising prevalence of erectile dysfunction (ED)

The etiology of ED can be attributed to multiple factors, such as diabetes mellitus, testosterone deficiency, prostate cancer, obesity, hypertension, and hyperlipidemia. In addition, the consumption of certain medicines and substance abuse can lead to ED. As most of these factors are related to lifestyle changes, the prevalence of ED is increasing globally. Rapid urbanization, and the inherent lifestyle changes, along with high stress at the workplace are rendering young men more susceptible to ED. Thus, the increase in the incidence of ED is expected to boost the adoption of PDE inhibitors and drive the market at a CAGR of almost 6% during the forecast period.

Rising burden of chronic diseases

Chronic diseases are among the leading causes of death and contribute to a significant portion of annual healthcare expenditure. Rising healthcare costs associated with chronic diseases such as heart disease, stroke, diabetes and prediabetes is expected to lead to an increase in the adoption of PDE5 inhibitors. Thus, an increase in the economic and health burden of these diseases will ensure continuous or increased use of PDE5 inhibitors for their remission, which will promote market growth during the forecast period.

Competitive Landscape

With the presence of several major players, the global phosphodiesterase inhibitors market is fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading phosphodiesterase inhibitors manufacturers, that include Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., Vivus Inc.

Also, the phosphodiesterase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer AG
  • Eli LillyCo.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Vivus Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: PIPELINE LANDSCAPE

PART 07: MARKET SEGMENTATION BY APPLICATION
  • Market segmentation by application
  • Comparison by application
  • Oral - Market size and forecast 2018-2023
  • Topical - Market size and forecast 2018-2023
  • Other RoA - Market size and forecast 2018-2023
  • Market opportunity by application
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Application of novel technologies for PDE inhibitors development
  • Growing geriatric population
  • Rising burden of chronic diseases
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Vivus Inc.
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
PART 16: About the Author
    Exhibit 1: Global pharmaceuticals market
    Exhibit 2: Segments of global pharmaceuticals market
    Exhibit 3: Market characteristics
    Exhibit 4: Market segments
    Exhibit 5: Some of the commercially available PDE inhibitors
    Exhibit 6: Disease targets for different PDE inhibitors
    Exhibit 7: Market definition - Inclusions and exclusions checklist
    Exhibit 8: Market size 2018
    Exhibit 9: Global market: Size and forecast 2018-2023 ($ millions)
    Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
    Exhibit 11: Five forces analysis 2018
    Exhibit 12: Five forces analysis 2023
    Exhibit 13: Bargaining power of buyers
    Exhibit 14: Bargaining power of suppliers
    Exhibit 15: Threat of new entrants
    Exhibit 16: Threat of substitutes
    Exhibit 17: Threat of rivalry
    Exhibit 18: Market condition - Five forces 2018
    Exhibit 19: Some of the phase III clinical trials of PDE inhibitors
    Exhibit 20: Application - Market share 2018-2023 (%)
    Exhibit 21: Comparison by application
    Exhibit 22: Oral - Market size and forecast 2018-2023 ($ millions)
    Exhibit 23: Advantages of tablet dosage form
    Exhibit 24: Oral - Year-over-year growth 2019-2023 (%)
    Exhibit 25: Topical - Market size and forecast 2018-2023 ($ millions)
    Exhibit 26: Topical - Year-over-year growth 2019-2023 (%)
    Exhibit 27: Other RoA - Market size and forecast 2018-2023 ($ millions)
    Exhibit 28: Other RoA - Year-over-year growth 2019-2023 (%)
    Exhibit 29: Market opportunity by application
    Exhibit 30: Customer landscape
    Exhibit 31: Market share by geography 2018-2023 (%)
    Exhibit 32: Geographic comparison
    Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
    Exhibit 34: North America - Year-over-year growth 2019-2023 (%)
    Exhibit 35: Top 3 countries in North America
    Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
    Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
    Exhibit 38: Top 3 countries in Europe
    Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions)
    Exhibit 40: Asia - Year-over-year growth 2019-2023 (%)
    Exhibit 41: Top 3 countries in Asia
    Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions)
    Exhibit 43: ROW - Year-over-year growth 2019-2023 (%)
    Exhibit 44: Top 3 countries in ROW
    Exhibit 45: Key leading countries
    Exhibit 46: Market opportunity
    Exhibit 47: Role of PDE5 inhibitors in ED
    Exhibit 48: Sales of PDE5 inhibitors after the launch of generics ($ millions)
    Exhibit 49: Impact of drivers and challenges
    Exhibit 50: CDC statistics about chronic diseases in geriatric population in the US over the past few years
    Exhibit 51: Geriatric population scenario in the US
    Exhibit 52: Vendor landscape
    Exhibit 53: Landscape disruption
    Exhibit 54: Vendors covered
    Exhibit 55: Vendor classification
    Exhibit 56: Market positioning of vendors
    Exhibit 57: Bayer AG - Vendor overview
    Exhibit 58: Bayer AG - Product segments
    Exhibit 59: Bayer AG - Organizational developments
    Exhibit 60: Bayer AG - Geographic focus
    Exhibit 61: Bayer AG - Segment focus
    Exhibit 62: Bayer AG - Key offerings
    Exhibit 63: Bayer AG - Key customers
    Exhibit 64: Eli Lilly and Co. - Vendor overview
    Exhibit 65: Eli Lilly and Co. - Business segments
    Exhibit 66: Eli Lilly and Co. - Organizational developments
    Exhibit 67: Eli Lilly and Co. - Geographic focus
    Exhibit 68: Eli Lilly and Co. - Segment focus
    Exhibit 69: Eli Lilly and Co. - Key offerings
    Exhibit 70: Eli Lilly and Co. - Key customers
    Exhibit 71: GlaxoSmithKline Plc - Vendor overview
    Exhibit 72: GlaxoSmithKline Plc - Business segments
    Exhibit 73: GlaxoSmithKline Plc - Organizational developments
    Exhibit 74: GlaxoSmithKline Plc - Geographic focus
    Exhibit 75: GlaxoSmithKline Plc - Segment focus
    Exhibit 76: GlaxoSmithKline Plc - Key offerings
    Exhibit 77: GlaxoSmithKline Plc - Key customers
    Exhibit 78: Pfizer Inc. - Vendor overview
    Exhibit 79: Pfizer Inc. - Business segments
    Exhibit 80: Pfizer Inc. - Organizational developments
    Exhibit 81: Pfizer Inc. - Geographic focus
    Exhibit 82: Pfizer Inc. - Segment focus
    Exhibit 83: Pfizer Inc. - Key offerings
    Exhibit 84: Pfizer Inc. - Key customers
    Exhibit 85: Vivus Inc. - Vendor overview
    Exhibit 86: Vivus Inc. - Business segments
    Exhibit 87: Vivus Inc. - Organizational developments
    Exhibit 88: Vivus Inc. - Geographic focus
    Exhibit 89: Vivus Inc. - Key offerings
    Exhibit 90: Vivus Inc. - Key customers
    Exhibit 91: Validation techniques employed for market sizing
    Exhibit 92: Definition of market positioning of vendors
    Note: Product cover images may vary from those shown
    3 of 4

    Loading
    LOADING...

    4 of 4

    FEATURED COMPANIES

    • Bayer AG
    • Eli LillyCo.
    • GlaxoSmithKline Plc
    • Pfizer Inc.
    • Vivus Inc.
    • MORE
    The following companies are recognised as the key players in the global phosphodiesterase inhibitors market: Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., Vivus Inc.

    Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the rising burden of chronic diseases”

    According to the report, one of the major drivers for this market is the rising prevalence of erectile dysfunction (ED).

    Further, the report states that one of the major factors hindering the growth of this market is the potent drug interactions of PDE inhibitors.

    The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
    Note: Product cover images may vary from those shown
    5 of 4
    • Bayer AG
    • Eli LillyCo.
    • GlaxoSmithKline Plc
    • Pfizer Inc.
    • Vivus Inc.
    Note: Product cover images may vary from those shown
    Adroll
    adroll